Fosamax Plateau & Non-Response Troubleshooting

What Counts as an Alendronate Plateau or Non-Response?

Clinicians need a precise definition before acting. A plateau means BMD has stabilized after an initial gain and is no longer changing significantly. Non-response means BMD is declining or a fragility fracture occurs despite ongoing therapy. These are different clinical problems requiring different responses.

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) established that alendronate 10 mg daily reduced vertebral fracture risk by 47% and hip fracture risk by 51% over three years compared with placebo [1]. Most of the BMD gain in FIT occurred in the first 12 months, with the spine reaching a mean increase of 6.2% and the femoral neck reaching 4.7% at 36 months [1]. After year two, the absolute BMD change per year slows to less than 0.5% at most skeletal sites.

This slowdown is pharmacologically expected. Alendronate binds to hydroxyapatite in resorption lacunae, inhibiting osteoclast function and reducing bone turnover by 50 to 70 percent within three to six months [2]. Once the remodeling space has been filled and turnover is suppressed, the engine producing further density gains is largely gone.

Defining True Non-Response

The American Association of Clinical Endocrinology (AACE) defines non-response operationally as: one or more incident fragility fractures after at least 12 months of adequate therapy, or a significant decline in BMD (greater than the least significant change at the testing facility, usually 3 to 4 percent at the spine) on two consecutive DXA scans [3].

A single low DXA reading is not enough. Measurement error, positioning differences, and machine drift all contribute noise. Two consecutive DXA scans showing decline, confirmed at least 12 months apart, are needed before changing therapy.

The Significance of Bone Turnover Markers

Bone turnover markers (BTMs) provide earlier signal than DXA. Serum C-terminal telopeptide of type I collagen (CTX) and urinary N-terminal telopeptide (NTX) reflect osteoclast activity and should fall 50 to 70 percent from baseline within three to six months of starting alendronate [4]. A CTX that has not fallen at least 25 percent after six months of self-reported adherence strongly suggests malabsorption or non-adherence, and should prompt a clinical review before the next DXA.

The International Osteoporosis Foundation recommends checking a fasting serum CTX or urinary NTX at baseline and again at three to six months to monitor pharmacodynamic response [4].

Why Alendronate Stops Working: The Most Common Causes

Most apparent alendronate failures are not failures of the drug itself. They are failures of delivery, absorption, or patient selection.

Poor Adherence

Adherence data for weekly alendronate are sobering. A retrospective cohort study of more than 35,000 postmenopausal women found that fewer than 50 percent were still taking their bisphosphonate at 12 months, and those with a medication possession ratio below 80 percent had no statistically significant fracture reduction compared with untreated controls [5]. The 70 mg weekly formulation was developed specifically to improve adherence over the original 10 mg daily tablet, but real-world persistence remains poor.

Before ordering any advanced workup, confirm adherence directly. Ask the patient to describe exactly how they take the medication: empty stomach, 30 to 60 minutes before any food or other drug, with 6 to 8 ounces of plain water, and remaining upright for at least 30 minutes. Each of these steps matters for absorption.

Gastrointestinal Malabsorption

Alendronate is already poorly absorbed under ideal conditions, with oral bioavailability of roughly 0.6 to 0.7 percent [6]. Any upper GI pathology reduces this further. Celiac disease, atrophic gastritis, proton pump inhibitor use, and Roux-en-Y gastric bypass surgery all impair bisphosphonate absorption meaningfully.

A serum 25-hydroxyvitamin D below 30 ng/mL will also blunt the response. Without adequate vitamin D and calcium substrate, newly mineralized osteoid cannot calcify properly, and measured BMD gains are reduced. The Endocrine Society recommends maintaining 25-OH-D at 40 to 60 ng/mL in patients being treated for osteoporosis [7].

Secondary Causes of Bone Loss

Secondary osteoporosis is present in up to 30 percent of postmenopausal women and more than 50 percent of men with osteoporosis [8]. Common culprits include:

• Primary hyperparathyroidism (elevated PTH, elevated or high-normal calcium)
• Hyperthyroidism (suppressed TSH)
• Hypercortisolism (Cushing syndrome)
• Hypogonadism in men (low total testosterone)
• Multiple myeloma or metastatic bone disease
• Chronic kidney disease (GFR <35 mL/min per 1.73 m² is a contraindication to bisphosphonates)

A targeted secondary workup in any patient with apparent non-response should include serum calcium, PTH, TSH, 25-OH-D, 24-hour urine calcium, complete metabolic panel, serum protein electrophoresis, and testosterone in men [3].

How to Systematically Evaluate a Patient With a Suspected Plateau

A structured approach prevents premature therapy changes and identifies reversible causes.

Step 1: Confirm Adherence and Administration Technique

Start with a non-judgmental medication review. Patients frequently take alendronate with coffee, skip doses, or lie down immediately after administration. Any of these behaviors reduces bioavailability and may fully explain apparent non-response.

Step 2: Check Bone Turnover Markers

Order a fasting serum CTX (morning sample, no food after midnight). A value in the normal premenopausal range (CTX below 100 pg/mL in most assays) confirms adequate suppression of bone resorption. A CTX in the upper-normal or elevated range despite reported adherence points toward malabsorption or ongoing secondary bone loss.

Step 3: Review Vitamin D and Calcium Status

Check a 25-OH-D level and a 24-hour urine calcium. Target 25-OH-D is 40 to 60 ng/mL. A 24-hour urine calcium below 100 mg suggests either low calcium intake, malabsorption, or severe vitamin D deficiency. Above 300 mg suggests hypercalciuria, which may itself be driving bone loss and requires separate management.

Step 4: Rule Out Secondary Osteoporosis

Run the secondary workup listed above. Treat any identified secondary cause before changing the bisphosphonate. A patient with undiagnosed celiac disease will not respond to any oral agent until intestinal absorption is restored.

Step 5: Reassess Fracture Risk

FRAX (the WHO fracture risk assessment tool) can be recalculated at the time of apparent plateau [9]. If the 10-year probability of major osteoporotic fracture has crossed above 20 percent or hip fracture above 3 percent, escalation is appropriate regardless of BMD trajectory.

The Drug Holiday Question: When to Stop, When to Continue

After five years of oral bisphosphonate therapy, the AACE/ACE 2022 guidelines recommend reassessing fracture risk to determine whether a drug holiday is appropriate [3]. Bisphosphonates accumulate in bone and continue to exert antifracture effects for one to three years after cessation. This residual effect is more pronounced with alendronate than with any other oral bisphosphonate, because of its high bone affinity.

The FLEX trial (N=1,099) randomized women who had taken alendronate for five years to continue for another five years or switch to placebo [10]. Women who continued alendronate had a 55 percent lower rate of clinical vertebral fractures at 10 years (2.4% vs. 5.3%, P<0.001) but showed no significant difference in hip or nonvertebral fracture rates compared with the placebo group [10]. This means the benefit of continuing beyond five years is vertebra-specific and most meaningful in patients with vertebral fractures or very low BMD.

Who Should Take a Holiday

Patients with a T-score above -2.5 at both hip and spine after five years of therapy, and no history of hip or vertebral fracture, are candidates for a one-to-three-year drug holiday [3]. During the holiday, annual bone turnover markers can signal when residual suppression is waning (CTX rising above premenopausal range), at which point therapy should resume or change.

Who Should Not Take a Holiday

Patients with a T-score at or below -2.5, a prior hip or vertebral fracture, or ongoing glucocorticoid exposure should continue therapy or transition to a more potent agent [3]. A drug holiday in these individuals carries meaningful fracture risk without compensating benefit.

When to Switch: Choosing the Next Agent

Confirmed non-response after ruling out adherence failure and secondary causes warrants a therapy change. The choice depends on fracture history, BMD, renal function, and patient preference.

Switching to Zoledronic Acid

Zoledronic acid 5 mg IV once yearly is an appropriate switch for patients with adherence difficulties or suspected GI malabsorption, because IV administration bypasses gut absorption entirely. The HORIZON-Key Fracture Trial (N=7,765) showed zoledronic acid reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over three years compared with placebo [11]. For patients who have already taken alendronate for three or more years, the residual bone-bound drug provides some background effect, but zoledronic acid will produce additional BTM suppression and further BMD gain in most patients.

Switching to Denosumab

Denosumab 60 mg subcutaneous every six months is an effective alternative, particularly for patients with renal impairment where bisphosphonates are contraindicated (GFR <35 mL/min per 1.73 m²). The FREEDOM trial (N=7,808) demonstrated a 68% reduction in vertebral fractures and a 40% reduction in hip fractures over 36 months [12]. Patients switching from alendronate to denosumab in the FREEDOM Extension showed continued BMD gains for up to 10 years of total denosumab exposure [12].

One caution: if denosumab is ever stopped, bone turnover rebounds rapidly and multiple vertebral fractures can occur within 12 to 18 months. Any patient starting denosumab needs a clear plan for sequential therapy upon discontinuation, typically transitioning to a bisphosphonate to preserve the denosumab-gained bone.

Anabolic Agents: Romosozumab and Teriparatide

Patients with very high fracture risk, defined by the AACE as a T-score at or below -3.0, multiple prior fractures, or fracture on antiresorptive therapy, should receive an anabolic agent first [3].

Romosozumab (Evenity) 210 mg SC monthly for 12 months inhibits sclerostin, simultaneously increasing bone formation and decreasing resorption. The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone, and the romosozumab-to-alendronate sequence reduced vertebral fractures by 48% and clinical fractures by 27% compared with alendronate alone at 24 months [13]. Romosozumab carries an FDA boxed warning for cardiovascular events and should not be used in patients with a recent myocardial infarction or stroke [14].

Teriparatide (Forteo) 20 mcg SC daily for up to 24 months stimulates osteoblast activity and produces spine BMD gains of 9 to 13 percent over two years [15]. After teriparatide is stopped, an antiresorptive agent must follow immediately to prevent rapid bone loss.

Practical Decision Points

For most patients with confirmed alendronate non-response and moderate fracture risk, zoledronic acid or denosumab are the first switch options. For high-fracture-risk patients, the anabolic-then-antiresorptive sequence produces larger absolute BMD gains and better fracture reduction than staying on oral therapy.

Managing Glucocorticoid-Induced Osteoporosis: A Special Case

Patients taking prednisone 5 mg or more daily for three or more months are at particularly high risk of rapid bone loss and fracture. The 2022 American College of Rheumatology (ACR) guideline recommends oral bisphosphonates as first-line therapy for most adults starting long-term glucocorticoids [16]. However, glucocorticoids suppress osteoblast function through mechanisms that bisphosphonates do not fully counteract.

Patients on chronic glucocorticoids who show BMD loss on alendronate should be considered for teriparatide rather than simply switching to another antiresorptive. The GIOP-Teriparatide trial (N=428) showed teriparatide produced significantly greater spine BMD gains than alendronate in glucocorticoid-exposed patients at 18 and 36 months, with a 51% lower rate of new vertebral fractures [15].

Monitoring After a Therapy Change

After switching therapy, repeat DXA in 12 months rather than the standard 24-month interval, because the first post-switch scan establishes whether the new agent is working. BTMs should be checked at three to six months post-switch. A rising BTM after switching to an antiresorptive, or a failure of BTM to rise after switching to an anabolic, again prompts a secondary-cause workup.

Serum calcium should be checked one to two weeks after the first dose of denosumab or zoledronic acid, because hypocalcemia is a clinically significant risk, especially in vitamin D-deficient patients. The FDA label for zoledronic acid requires that patients be adequately supplemented with calcium and vitamin D before IV infusion [14].

The ACE inhibitor or thiazide diuretic a patient takes for hypertension may also interact. Thiazides reduce urinary calcium excretion and may mildly augment the BMD effect of bisphosphonates. Loop diuretics increase urinary calcium loss and can worsen bone turnover.

Calcium and Vitamin D Optimization: Non-Negotiable Co-Therapy

No antiresorptive or anabolic agent works optimally without adequate calcium and vitamin D. The National Osteoporosis Foundation recommends 1,000 to 1,200 mg elemental calcium daily from diet plus supplements combined, and 800 to 1,000 IU vitamin D3 daily as a minimum [17]. Many osteoporosis patients need 2,000 IU daily or more to maintain 25-OH-D above 40 ng/mL, particularly in northern latitudes or with limited sun exposure.

Calcium carbonate requires stomach acid for absorption and should be taken with food. Calcium citrate absorbs regardless of acid status and is preferred in patients taking proton pump inhibitors or with atrophic gastritis [17].

Patients with a documented calcium intake above 1,200 mg daily from all sources do not benefit from additional supplementation and may face increased cardiovascular risk from excess supplemental calcium, based on observational data, though this remains an active area of debate [17].

Atypical Femoral Fractures and Osteonecrosis of the Jaw: Context for Long-Term Therapy

Clinicians and patients often cite rare adverse events as reasons to stop alendronate prematurely. The absolute risk of atypical femoral fracture (AFF) with bisphosphonate use is approximately 3.2 to 50 per 100,000 patient-years, increasing with duration of use beyond five to eight years [18]. This compares with an annual hip fracture rate of 1,500 to 3,000 per 100,000 untreated women over age 70 [1]. The fracture prevention benefit vastly exceeds the AFF risk in high-risk patients.

Osteonecrosis of the jaw (ONJ) occurs in roughly 1 in 10,000 to 1 in 100,000 patients taking oral bisphosphonates for osteoporosis (the risk is substantially higher in patients receiving high-dose IV bisphosphonates for cancer-related bone disease) [18]. Dental extraction and poor oral hygiene are the primary precipitants. Patients should have a dental evaluation before starting long-term therapy and maintain regular dental care throughout.

Neither AFF nor ONJ is a reason to withhold bisphosphonate therapy from patients who need it. They are reasons to reassess therapy duration and inform patients appropriately.